Tokyo, April 29 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061398) titled 'A Retrospective Study of the Effects of Pemafibrate in Patients with Dyslipidemia Complicated by Metabolic Dysfunction-Associated Steatotic Liver Disease' on April 28.
Study Type:
Observational
Primary Sponsor:
Institute - Kagawa university
Condition:
Condition - Patients with dyslipidemia complicated by steatotic liver disease/MASLD
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - This study aims to assess the clinical course following pemafibrate administration in patients with dyslipidemia complicated by MASLD who are regularly followed at our hospital, with comparisons according to the presence or absence of impaired glucose tolerance, and to evaluate the effects of pemafibrate on glucose metabolism and MASLD.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with dyslipidemia complicated by fatty liver disease/MASLD who attended the participating medical institution during the study period, received pemafibrate, and for whom the presence or absence of impaired glucose tolerance can be confirmed.
Patients whose required data items, as described below, are recorded in the electronic medical records.
Key exclusion criteria - Patients for whom the required data items cannot be collected from the medical records.
Target Size - 495
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2026 Year 01 Month 16 Day
Date of IRB - 2026 Year 01 Month 16 Day
Anticipated trial start date - 2026 Year 01 Month 20 Day
Last follow-up date - 2026 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070251
Disclaimer: Curated by HT Syndication.
